Key Figures 2012
Group sales Core operating profit Core earnings per share Operating free cash flow R & D investment Dividend 2
45,499 17,160 13.62 15,389 8,475 7.35
millions of CHF millions of CHF CHF millions of CHF millions of CHF CHF
+4% +11% +10% +10% +2% +8%
(CER) 1 (CER) (CER) (CER) (CER) (CER)
Total Shareholder Return 2012 The value of CHF 100 3 invested 1/1/2012, for the period ending 31/12/2012 125
121 118 117
90 Dec 2011
Roche GS, Price = 184.00
Roche B, Price = 186.90
Peer Set Index
Patients on clinical trials Number of employees 4
1 CER: Constant exchange rates (average full-year 2011). 2 Proposed by the Board of Directors. 3 Prices translated at constant CHF exchange rates: USD=0.90; EUR=1.20; 100 JPY=1.10; GBP=1.40. 4 Full-time equivalents.
Key Events 2012
At the Roche Annual General Meeting in 2012, shareholders authorised a 3% dividend increase to CHF 6.80 per share and non-voting equity. It was the company’s 25 th dividend increase in as many years. Management changes: Daniel O’Day, former Head of Roche Diagnostics, was appointed the new Head of Roche Pharma. Roland Diggelmann has assumed the position of Head of Roche Diagnostics. Daniel O’Day Roland Diggelmann
Roche continued to streamline its research and develop ment activities, taking the decision to close its site in Nutley, New Jersey, USA. The respective R & D activities are being consolidated in Switzerland and Germany.
Our latestage pipeline made considerable progress in 2012, with 11 out of 14 clinical trials delivering positive results, underpinning the strength of our innovation strategy.
The FDA approved Erivedge (vismodegib), a first-in-class Hedgehog Pathway Inhibitor for adults with advanced basal cell carcinoma. The FDA approved Perjeta (pertuzumab) for patients with HER2-positive metastatic breast cancer. This new personalised medicine gives patients more time without their disease worsening.
New data from the Phase III EMILIA study showed that Roche’s trastuzumab emtansine (T–DM1) significantly improved survival of people with HER2-positive metastatic breast cancer. Roche has filed for approval at the FDA and the EMA.
After the second interim data analysis of the dal-OUTCOMES trial, Roche decided to discontinue the development of dalcetrapib, a medicine to lower cardiovascular risks.
In 2012 we reduced our water consumption by 8.6% and our greenhouse gas emissions by 2.6%. With this, we are well on track to reach our five-year goal of a 10% improvement in efficiency by 2014. The second Transnet Phelophepa Healthcare Train was inaugurated in South Africa. Roche doubled its support, now reaching over 550,000 people a year in rural South Africa through the train’s various services.
Roche has been recognised as a great place to work, achieving top rankings in prestigious award listings worldwide in 2012.
Roche has been named Healthcare Supersector Leader in the Dow Jones Sustainability Indexes (DJSI) for the fourth consecutive year. The ranking is a confirmation of Roche’s commitment to long-term sustainable value creation.
New US guidelines recognise the benefit of genotyping the human papillomavirus (HPV) 16 and 18, the principal causes of cervical cancer in women. The FDA cleared the AccuChek Combo system, Roche’s new interactive insulin pump system for people with diabetes, and the Accu-Chek Nano SmartView system.
Roche Applied Science and Diabetes Care initiated restructuring measures to sustain long-term profitability.
Roche launched GUIDEIT, a clinical trial involving the cardiac marker NT-proBNP to guide therapy in heart failure patients.
The value of innovation
ROCHE AT A GLANCE
Who we are
At Roche, we focus on fitting...